Floatz logo

LEUPROLIDE

Metastases-free Survival

Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápicprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

170 Active assets in the Metastases-free Survival cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Ipilimumab
7 Hills Pharma, LLC
Phase 3BB

View all 50 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →